Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Molecules › Retatrutide

Retatrutide

GIP/GLP-1/GCG · s.c. · Eli Lilly

Data cut 12 November 2026 · page built 16 November 2026 · 15 trial arms · 10 trials with results · 15 registered trials · see on the pipeline board

Summary

Also known as
LY3437943
Mechanism
GIP/GLP-1/GCG
Route
s.c.
Company
Eli Lilly
Highest development stage
phase 3
Status (as of data cut)
Phase 3 positive: TRIUMPH-1 (NEJM 2026), TRIUMPH-2/-3 and TRIUMPH-4 toplines; TRANSCEND-T2D-1 at EASD 2026 verify
Next milestone
US submission planned Q1 2027

Sources for the status

Indications: regulatory and evidence status

IndicationCodeStatusEvidence
Obesity3 positive phase 3Positive phase 3 (TRIUMPH-1 published; TRIUMPH-3 topline); US submission planned Q1 2027TRIUMPH-1; TRIUMPH-2/-3 topline, Lilly press release (Jul 2026)
T2D3 positive phase 3Positive phase 3 (TRANSCEND-T2D-1; TRIUMPH-2 HbA1c)TRANSCEND-T2D-1 (EASD 2026); TRIUMPH-2 topline, Lilly press release (Jul 2026)
CV outcomes2 phase 3 ongoingCV and kidney outcomes trial ongoingTRIUMPH-OUTCOMES
CKD2 phase 3 ongoingPhase 3 ongoingKidney study in T2D
HFpEF0 no data
MASH2 phase 3 ongoingPhase 3 ongoing
Sleep apnoea3 positive phase 3Positive phase 3: TRIUMPH-1-OSA and TRIUMPH-2-OSA (NEJM 2026)TRIUMPH-1-OSA / TRIUMPH-2-OSA, NEJM 2026
Knee OA3 positive phase 3Positive phase 3: TRIUMPH-4 and TRIUMPH-1-OA (NEJM, Nov 2026)TRIUMPH-4 / TRIUMPH-1-OA, NEJM 2026; TRIUMPH-4
Alzheimer's0 no data

4 = approved / in a label (FDA, EMA or NMPA), 3 = positive phase 3, 2 = phase 3 ongoing or completed without public results, 1 = phase 2 or signal only, 0 = no data, −1 = negative phase 3/4. L = label, P = PubMed, T = registry.

US prescribing information: indications

Verbatim section 1 of the current FDA label (DailyMed), as checked by the atlas.

Trial arms: weight, HbA1c and tolerability

TrialArmPopulationWeeksnWeight, efficacyWeight, treatment-policyHbA1c, ppAE discontinuation, %Any discontinuation, %Nausea, %Vomiting, %SAE, %SBP, mmHgStatus
Retatrutide phase 2 (T2D)retatrutide 12 mgt2d36281−16.9 % vs −3.0 %
Δ −13.9 pp
—−2.0 vs +0.0——————seed
Retatrutide phase 2 (obesity)retatrutide 12 mgobesity48338−24.2 % vs −2.1 %
Δ −22.1 pp
——16.0 vs 0.0—45.0 vs 11.019.0 vs 1.03.0 vs 4.0—verified
Retatrutide phase 2 (obesity)retatrutide 8 mg (start 4 mg)obesity48338−23.9 % vs −2.1 %
Δ −21.8 pp
——6.0 vs 0.0—60.0 vs 11.026.0 vs 1.06.0 vs 4.0—verified
Retatrutide phase 2 (obesity)retatrutide 4 mg (start 4 mg)obesity48338−17.8 % vs −2.1 %
Δ −15.7 pp
——9.0 vs 0.0—36.0 vs 11.012.0 vs 1.06.0 vs 4.0—verified
TRANSCEND-T2D-1 (T2D monotherapy)retatrutide 12 mgt2d40537−16.8 % vs −2.5 %
Δ −14.3 pp
−16.8 % vs −2.5 %
Δ −14.3 pp
−1.9 vs −0.85.1 vs 0.0—————verified
TRANSCEND-T2D-2 (vs semaglutide 2 mg)retatrutide 9 mg vs semaglutide 2 mg (active)t2d80—−19.5 %—−2.24.8—21.210.2——press release
TRANSCEND-T2D-2 (vs semaglutide 2 mg)retatrutide 12 mg vs semaglutide 2 mg (active)t2d80—−20.9 %—−2.27.9—23.815.0——press release
TRIUMPH-1retatrutide 4 mgobesity80584−19.0 % vs −2.2 %
Δ −16.8 pp
−17.6 % vs −3.9 %
Δ −13.7 pp
—4.1 vs 4.6—28.6 vs 14.810.6 vs 4.87.7 vs 5.5−7.6 vs −1.9verified
TRIUMPH-1retatrutide 9 mgobesity80584−25.9 % vs −2.2 %
Δ −23.7 pp
−23.7 % vs −3.9 %
Δ −19.8 pp
—6.5 vs 4.6—38.4 vs 14.822.8 vs 4.87.7 vs 5.5−9.8 vs −1.9verified
TRIUMPH-1retatrutide 12 mgobesity80584−28.3 % vs −2.2 %
Δ −26.1 pp
−25.0 % vs −3.9 %
Δ −21.1 pp
—11.2 vs 4.6—42.4 vs 14.825.3 vs 4.810.5 vs 5.5−10.4 vs −1.9verified
TRIUMPH-2 (obesity + T2D)retatrutide 4 mgt2d80—−12.7 % vs −4.0 %
Δ −8.7 pp
−11.9 % vs −5.1 %
Δ −6.8 pp
−1.4 vs −0.53.0 vs 5.010.3 vs 21.514.0 vs 8.06.0 vs 4.08.0 vs 8.0−5.0 vs −2.7verified
TRIUMPH-2 (obesity + T2D)retatrutide 9 mgt2d80—−19.1 % vs −4.0 %
Δ −15.1 pp
−16.8 % vs −5.1 %
Δ −11.7 pp
−1.5 vs −0.511.0 vs 5.019.4 vs 21.521.0 vs 8.010.0 vs 4.09.0 vs 8.0−7.4 vs −2.7verified
TRIUMPH-2 (obesity + T2D)retatrutide 12 mgt2d80—−20.8 % vs −4.0 %
Δ −16.8 pp
−18.8 % vs −5.1 %
Δ −13.7 pp
−1.4 vs −0.57.0 vs 5.013.9 vs 21.528.0 vs 8.016.0 vs 4.09.0 vs 8.0−9.7 vs −2.7verified
TRIUMPH-4 (obesity + knee osteoarthritis)retatrutide 9 mgobesity68148−26.4 % vs −2.1 %
Δ −24.3 pp
−20.0 % vs −4.6 %
Δ −15.4 pp
—12.9 vs 4.0———9.5 vs 2.0—verified
TRIUMPH-4 (obesity + knee osteoarthritis)retatrutide 12 mgobesity68148−28.7 % vs −2.1 %
Δ −26.6 pp
−23.7 % vs −4.6 %
Δ −19.1 pp
—18.2 vs 4.0———10.8 vs 2.0−14.0verified

Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.

Notes

Verbatim quotes from the source (85)
  • retatrutide 12 mg · ae_dc · Table 3, AEs leading to discontinuation
    Any event 0 5 (7) 2 (6) 3 (9) 5 (14) 2 (6) 10 (16) 27 (8)
  • retatrutide 12 mg · nausea · Table 3
    Nausea 8 (11) 10 (14) 6 (18) 12 (36) 6 (17) 21 (60) 28 (45) 91 (27)
  • retatrutide 12 mg · vomiting · Table 3
    Vomiting 1 (1) 2 (3) 4 (12) 4 (12) 2 (6) 9 (26) 12 (19) 34 (10)
  • retatrutide 12 mg · sae · Table 3
    Serious adverse event 3 (4) 3 (4) 0 2 (6) 1 (3) 2 (6) 2 (3) 13 (4)
  • retatrutide 12 mg · weight_eff · Results, Changes in Body Weight
    −24.2% in the 12-mg group with an initial dose of 2 mg
  • retatrutide 8 mg (start 4 mg) · ae_dc · Table 3
    8 mg (initial 4 mg): 2 (6%)
  • retatrutide 8 mg (start 4 mg) · nausea · Table 3
    Nausea 8 (11) 10 (14) 6 (18) 12 (36) 6 (17) 21 (60) 28 (45) 91 (27)
  • retatrutide 8 mg (start 4 mg) · vomiting · Table 3
    Vomiting 1 (1) 2 (3) 4 (12) 4 (12) 2 (6) 9 (26) 12 (19) 34 (10)
  • retatrutide 8 mg (start 4 mg) · sae · Table 3
    Serious adverse event 3 (4) 3 (4) 0 2 (6) 1 (3) 2 (6) 2 (3) 13 (4)
  • retatrutide 8 mg (start 4 mg) · weight_eff · Results, Changes in Body Weight
    −23.9% in the 8-mg group (initial dose 4 mg)
  • retatrutide 4 mg (start 4 mg) · ae_dc · Table 3
    4 mg (initial 4 mg): 3 (9%)
  • retatrutide 4 mg (start 4 mg) · nausea · Table 3
    Nausea 8 (11) 10 (14) 6 (18) 12 (36) 6 (17) 21 (60) 28 (45) 91 (27)
  • retatrutide 4 mg (start 4 mg) · vomiting · Table 3
    Vomiting 1 (1) 2 (3) 4 (12) 4 (12) 2 (6) 9 (26) 12 (19) 34 (10)
  • retatrutide 4 mg (start 4 mg) · sae · Table 3
    Serious adverse event 3 (4) 3 (4) 0 2 (6) 1 (3) 2 (6) 2 (3) 13 (4)
  • retatrutide 4 mg (start 4 mg) · weight_eff · Results, Changes in Body Weight
    −17.8% in the 4-mg group with an initial dose of 4 mg
  • retatrutide 12 mg · weight_eff · Results
    The estimated mean percent change from BL in BW was -11.5% with 4 mg, -15.5% with 9 mg, -16.8% with 12 mg retatrutide vs -2.5% with placebo (all p<0.001).
  • retatrutide 12 mg · ae_dc · Results
    Discontinuation due to AEs occurred in 2.2% (4 mg), 4.5% (9 mg), and 5.1% (12 mg) participants treated with retatrutide, versus 0% with placebo.
  • retatrutide 12 mg · hba1c · Results
    The estimated mean change from BL in HbA1c was -1.7% (-18.5 mmol/mol) with 4 mg, -2.0% (-22.0 mmol/mol) with 9 mg, and -1.9% (-21.0 mmol/mol) with 12 mg retatrutide
  • retatrutide 4 mg · weight_eff · Results, Body-Weight Outcomes, paragraph 1
    The corresponding mean percent changes in body weight from baseline to week 80 for the efficacy-estimand calculation were −19.0%, −25.9%, and −28.3%, as compared with 2.2% with placebo
  • retatrutide 4 mg · weight_tp · Results, Body-Weight Outcomes, paragraph 1; Table 2
    −17.6% with the 4-mg dose, −23.7% with the 9-mg dose, and −25.0% with the 12-mg dose, as compared with −3.9% with placebo
  • retatrutide 4 mg · ae_dc · Table 3
    Leading to discontinuation of retatrutide or placebo‡ 24 (4.1) 38 (6.5) 65 (11.2) 27 (4.6)
  • retatrutide 4 mg · nausea · Table 3
    Nausea 167 (28.6) 224 (38.4) 247 (42.4) 87 (14.8)
  • retatrutide 4 mg · vomiting · Table 3
    Vomiting 62 (10.6) 133 (22.8) 147 (25.3) 28 (4.8)
  • retatrutide 4 mg · sae · Table 3
    Serious adverse event 45 (7.7) 45 (7.7) 61 (10.5) 32 (5.5)
  • retatrutide 4 mg · sbp · Table 2 (continued)
    Change in systolic blood pressure (95% CI) — mm Hg −7.6 (−8.6 to −6.5) −9.8 (−10.8 to −8.7) −10.4 (−11.6 to −9.2) −1.9 (−3.6 to −0.3)
  • retatrutide 9 mg · weight_eff · Results, Body-Weight Outcomes, paragraph 1
    The corresponding mean percent changes in body weight from baseline to week 80 for the efficacy-estimand calculation were −19.0%, −25.9%, and −28.3%, as compared with 2.2% with placebo
  • retatrutide 9 mg · weight_tp · Results, Body-Weight Outcomes, paragraph 1; Table 2
    −17.6% with the 4-mg dose, −23.7% with the 9-mg dose, and −25.0% with the 12-mg dose, as compared with −3.9% with placebo
  • retatrutide 9 mg · ae_dc · Table 3
    Leading to discontinuation of retatrutide or placebo‡ 24 (4.1) 38 (6.5) 65 (11.2) 27 (4.6)
  • retatrutide 9 mg · nausea · Table 3
    Nausea 167 (28.6) 224 (38.4) 247 (42.4) 87 (14.8)
  • retatrutide 9 mg · vomiting · Table 3
    Vomiting 62 (10.6) 133 (22.8) 147 (25.3) 28 (4.8)
  • retatrutide 9 mg · sae · Table 3
    Serious adverse event 45 (7.7) 45 (7.7) 61 (10.5) 32 (5.5)
  • retatrutide 9 mg · sbp · Table 2 (continued)
    Change in systolic blood pressure (95% CI) — mm Hg −7.6 (−8.6 to −6.5) −9.8 (−10.8 to −8.7) −10.4 (−11.6 to −9.2) −1.9 (−3.6 to −0.3)
  • retatrutide 12 mg · weight_eff · Results, Body-Weight Outcomes, paragraph 1
    The corresponding mean percent changes in body weight from baseline to week 80 for the efficacy-estimand calculation were −19.0%, −25.9%, and −28.3%, as compared with 2.2% with placebo
  • retatrutide 12 mg · weight_tp · Results, Body-Weight Outcomes, paragraph 1; Table 2
    −17.6% with the 4-mg dose, −23.7% with the 9-mg dose, and −25.0% with the 12-mg dose, as compared with −3.9% with placebo
  • retatrutide 12 mg · ae_dc · Table 3
    Leading to discontinuation of retatrutide or placebo‡ 24 (4.1) 38 (6.5) 65 (11.2) 27 (4.6)
  • retatrutide 12 mg · nausea · Table 3
    Nausea 167 (28.6) 224 (38.4) 247 (42.4) 87 (14.8)
  • retatrutide 12 mg · vomiting · Table 3
    Vomiting 62 (10.6) 133 (22.8) 147 (25.3) 28 (4.8)
  • retatrutide 12 mg · sae · Table 3
    Serious adverse event 45 (7.7) 45 (7.7) 61 (10.5) 32 (5.5)
  • retatrutide 12 mg · sbp · Table 2 (continued)
    Change in systolic blood pressure (95% CI) — mm Hg −7.6 (−8.6 to −6.5) −9.8 (−10.8 to −8.7) −10.4 (−11.6 to −9.2) −1.9 (−3.6 to −0.3)
  • retatrutide 9 mg · weight_eff · Article body, paragraph 4
    while those on 9 mg lost 26.4%
  • retatrutide 9 mg · ae_dc · Schnitzer TJ et al., NEJM 2026 (author accepted manuscript), Table 3
    Adverse events 19 27 (18.2) 6 (4.0) 52 (11.7) 4 (2.8) 12 (8.4) 22 (15.3) 9 (6.2) 47 (8.2) leading to (12.9)
  • retatrutide 9 mg · weight_tp · Schnitzer TJ et al., NEJM 2026 (author accepted manuscript), Table 2
    -20.0 (0.9) -23.7 (1.0) -4.6
  • retatrutide 9 mg · sae · Schnitzer TJ et al., NEJM 2026 (author accepted manuscript), Table 3
    Serious adverse 14 (9.5) 16 (10.8) 3 (2.0) 33 (7.4) 6 (4.2) 14 (9.8) 21 (14.6) 10 (6.9) 51 (8.9)
  • retatrutide 12 mg · weight_eff · Article body, paragraph 4
    patients receiving the 12 mg dose losing an average of 28.7% of their body weight
  • retatrutide 12 mg · ae_dc · Schnitzer TJ et al., NEJM 2026 (author accepted manuscript), Table 3
    Adverse events 19 27 (18.2) 6 (4.0)
  • retatrutide 12 mg · sbp · The Phase 3 TRIUMPH-4 Trial, paragraph 3
    At the highest dose, systolic blood pressure decreased by 14.0 mm Hg.
  • retatrutide 12 mg · weight_tp · Schnitzer TJ et al., NEJM 2026 (author accepted manuscript), Table 2
    -20.0 (0.9) -23.7 (1.0) -4.6
  • retatrutide 12 mg · sae · Schnitzer TJ et al., NEJM 2026 (author accepted manuscript), Table 3
    Serious adverse 14 (9.5) 16 (10.8) 3 (2.0)
  • retatrutide 4 mg · weight_eff · Results, paragraph 4 (efficacy estimand)
    –12·7% (SE 0·6) in the 4 mg group
  • retatrutide 4 mg · weight_tp · Results, paragraph 4; Table 2
    was −11·9% (SE 0·6; −12·9 kg [0·6]) with retatrutide 4 mg
  • retatrutide 4 mg · ae_dc · Results, paragraph 2; Figure 1
    Ten (3%) participants in the retatrutide 4 mg group
  • retatrutide 4 mg · disc_any · Figure 1
    30 discontinued study drug
  • retatrutide 4 mg · nausea · Results, safety paragraph; Table 3
    nausea in 40 [14%], 59 [21%], and 80 [28%] vs 23 [8%]
  • retatrutide 4 mg · vomiting · Results, safety paragraph; Table 3
    in 16 [6%], 29 [10%], and 45 [16%] vs 12 [4%]
  • retatrutide 4 mg · sae · Results, safety paragraph; Table 3
    Serious adverse events were reported by 24 (8%) in the retatrutide 4 mg group
  • retatrutide 4 mg · hba1c · Results, paragraph 6; Table 2
    The mean change from baseline to week 80 in HbA1c was −1·38% (SE 0·06) with retatrutide 4 mg
  • retatrutide 4 mg · sbp · Results, paragraph 8; Table 2
    −5·0 mm Hg [SE 0·7] with 4 mg
  • retatrutide 9 mg · weight_eff · Results, paragraph 4 (efficacy estimand)
    –19·1% (0·6) in the 9 mg group
  • retatrutide 9 mg · weight_tp · Results, paragraph 4; Table 2
    −16·8% (0·7; −18·3 kg [0·8]) with retatrutide 9 mg
  • retatrutide 9 mg · ae_dc · Results, paragraph 2; Figure 1
    31 (11%) in the retatrutide 9 mg group
  • retatrutide 9 mg · disc_any · Figure 1
    55 discontinued study drug
  • retatrutide 9 mg · nausea · Results, safety paragraph; Table 3
    nausea in 40 [14%], 59 [21%], and 80 [28%] vs 23 [8%]
  • retatrutide 9 mg · vomiting · Results, safety paragraph; Table 3
    in 16 [6%], 29 [10%], and 45 [16%] vs 12 [4%]
  • retatrutide 9 mg · sae · Results, safety paragraph; Table 3
    25 (9%) in the retatrutide 9 mg group
  • retatrutide 9 mg · hba1c · Results, paragraph 6; Table 2
    −1·50% (0·07) with retatrutide 9 mg
  • retatrutide 9 mg · sbp · Results, paragraph 8; Table 2
    –7·4 mm Hg [0·8] with 9 mg
  • retatrutide 12 mg · weight_eff · Results, paragraph 4 (efficacy estimand)
    and –20·8% (0·6) in the 12 mg group
  • retatrutide 12 mg · weight_tp · Results, paragraph 4; Table 2
    −18·8% (0·7; −20·7 kg [0·8]) with retatrutide 12 mg
  • retatrutide 12 mg · ae_dc · Results, paragraph 2; Figure 1
    21 (7%) in the retatrutide 12 mg group
  • retatrutide 12 mg · disc_any · Figure 1
    40 discontinued study drug
  • retatrutide 12 mg · nausea · Results, safety paragraph; Table 3
    nausea in 40 [14%], 59 [21%], and 80 [28%] vs 23 [8%]
  • retatrutide 12 mg · vomiting · Results, safety paragraph; Table 3
    in 16 [6%], 29 [10%], and 45 [16%] vs 12 [4%]
  • retatrutide 12 mg · sae · Results, safety paragraph; Table 3
    27 (9%) in the retatrutide 12 mg group
  • retatrutide 12 mg · hba1c · Results, paragraph 6; Table 2
    −1·45% (0·07) with retatrutide 12 mg
  • retatrutide 12 mg · sbp · Results, paragraph 8; Table 2
    −9·7 mm Hg [0·8] with 12 mg
  • retatrutide 9 mg · weight_eff · Results, paragraph 2 and efficacy estimand table
    Participants taking retatrutide lost an average of 44.3 lbs (19.5%; 9 mg) and 47.4 lbs (20.9%; 12 mg) compared to 20.9 lbs (9.4%) with Ozempic.
  • retatrutide 9 mg · ae_dc · Results, adverse events paragraph
    Treatment discontinuation rates due to adverse events were 4.8%, 7.9% vs. 2.7% with retatrutide 9 mg and 12 mg vs. Ozempic, respectively.
  • retatrutide 9 mg · nausea · Results, adverse events paragraph
    nausea (21.2%, 23.8% vs. 21.3%)
  • retatrutide 9 mg · vomiting · Results, adverse events paragraph
    vomiting (10.2%, 15.0% vs. 13.2%)
  • retatrutide 9 mg · hba1c · Results, paragraph 2 and efficacy estimand table
    both doses of retatrutide lowered A1C by an average of 2.2% compared to 1.8% with Ozempic at 80 weeks.
  • retatrutide 12 mg · weight_eff · Results, paragraph 2 and efficacy estimand table
    Participants taking retatrutide lost an average of 44.3 lbs (19.5%; 9 mg) and 47.4 lbs (20.9%; 12 mg) compared to 20.9 lbs (9.4%) with Ozempic.
  • retatrutide 12 mg · ae_dc · Results, adverse events paragraph
    Treatment discontinuation rates due to adverse events were 4.8%, 7.9% vs. 2.7% with retatrutide 9 mg and 12 mg vs. Ozempic, respectively.
  • retatrutide 12 mg · nausea · Results, adverse events paragraph
    nausea (21.2%, 23.8% vs. 21.3%)
  • retatrutide 12 mg · vomiting · Results, adverse events paragraph
    vomiting (10.2%, 15.0% vs. 13.2%)
  • retatrutide 12 mg · hba1c · Results, paragraph 2 and efficacy estimand table
    both doses of retatrutide lowered A1C by an average of 2.2% compared to 1.8% with Ozempic at 80 weeks.

Outcome trials

Other indications

TRIUMPH-1-OSA / TRIUMPH-2-OSA Retatrutide · Obstructive sleep apnoea + obesity (with or without T2D) · 80 weeks · n = 691 verified

AHI −24.4 (9 mg) and −21.9 (12 mg) events/h vs placebo without T2D; −14.4 and −15.1 with T2D (hybrid estimand, primary). Sub-studies nested in TRIUMPH-1 and TRIUMPH-2.

MeasureDrugControlDifference (95 % CI)Status
Apnea-hypopnea index, change from baseline (hybrid estimand) TRIUMPH-1-OSA, no T2D · 4 mg
week 80
−22.9−9.9−13.0 (−23.0 to −3.0) events/hverified
Apnea-hypopnea index, change from baseline (hybrid estimand) TRIUMPH-1-OSA, no T2D · 9 mg
week 80
−34.3−9.9−24.4 (−34.1 to −14.7) events/hverified
Apnea-hypopnea index, change from baseline (hybrid estimand) TRIUMPH-1-OSA, no T2D · 12 mg
week 80
−31.7−9.9−21.9 (−32.2 to −11.5) events/hverified
Apnea-hypopnea index, change from baseline (hybrid estimand) TRIUMPH-2-OSA, T2D · 4 mg
week 80
−19.2−10.3−8.9 (−15.9 to −2.0) events/hverified
Apnea-hypopnea index, change from baseline (hybrid estimand) TRIUMPH-2-OSA, T2D · 9 mg
week 80
−24.7−10.3−14.4 (−21.6 to −7.2) events/hverified
Apnea-hypopnea index, change from baseline (hybrid estimand) TRIUMPH-2-OSA, T2D · 12 mg
week 80
−25.4−10.3−15.1 (−22.5 to −7.7) events/hverified
Verbatim quotes (6)
  • Apnea-hypopnea index, change from baseline (hybrid estimand)
    −22.9 (−29.7 to −16.0)
  • Apnea-hypopnea index, change from baseline (hybrid estimand)
    −34.3 (−40.8 to −27.7)
  • Apnea-hypopnea index, change from baseline (hybrid estimand)
    −31.7 (−38.2 to −25.2)
  • Apnea-hypopnea index, change from baseline (hybrid estimand)
    −19.2 (−23.7 to −14.7)
  • Apnea-hypopnea index, change from baseline (hybrid estimand)
    −24.7 (−29.9 to −19.5)
  • Apnea-hypopnea index, change from baseline (hybrid estimand)
    −25.4 (−30.6 to −20.1)

TRIUMPH-4 / TRIUMPH-1-OA Retatrutide · Knee osteoarthritis + obesity · 68 weeks · n = 1019 verified

WOMAC pain −1.83 (9 mg) and −1.61 (12 mg) points vs placebo on a 0–10 scale at 68 weeks in TRIUMPH-4; −1.35, −1.61 and −1.77 (4/9/12 mg) at 80 weeks in TRIUMPH-1-OA (hybrid-treatment estimand). Weight −15.4 and −19.2 percentage points vs placebo in TRIUMPH-4 (treatment-regimen estimand).

MeasureDrugControlDifference (95 % CI)Status
WOMAC pain (0–10 NRS), change from baseline (hybrid-treatment estimand) TRIUMPH-4 · 9 mg
week 68
−4.0−2.1−1.8 (−2.4 to −1.3) pointsverified
WOMAC physical function (0–10 NRS), change from baseline (hybrid-treatment estimand) TRIUMPH-4 · 9 mg
week 68
−3.6−1.8−1.8 (−2.4 to −1.3) pointsverified
WOMAC pain (0–10 NRS), change from baseline (hybrid-treatment estimand) TRIUMPH-4 · 12 mg
week 68
−3.7−2.1−1.6 (−2.2 to −1.1) pointsverified
WOMAC physical function (0–10 NRS), change from baseline (hybrid-treatment estimand) TRIUMPH-4 · 12 mg
week 68
−3.6−1.8−1.8 (−2.3 to −1.2) pointsverified
WOMAC pain (0–10 NRS), change from baseline (hybrid-treatment estimand) TRIUMPH-1-OA · 4 mg
week 80
−3.2−1.9−1.4 (−1.9 to −0.8) pointsverified
WOMAC physical function (0–10 NRS), change from baseline (hybrid-treatment estimand) TRIUMPH-1-OA · 4 mg
week 80
−3.2−1.5−1.7 (−2.2 to −1.1) pointsverified
WOMAC pain (0–10 NRS), change from baseline (hybrid-treatment estimand) TRIUMPH-1-OA · 9 mg
week 80
−3.5−1.9−1.6 (−2.2 to −1.0) pointsverified
WOMAC physical function (0–10 NRS), change from baseline (hybrid-treatment estimand) TRIUMPH-1-OA · 9 mg
week 80
−3.4−1.5−1.9 (−2.5 to −1.3) pointsverified
WOMAC pain (0–10 NRS), change from baseline (hybrid-treatment estimand) TRIUMPH-1-OA · 12 mg
week 80
−3.6−1.9−1.8 (−2.3 to −1.2) pointsverified
WOMAC physical function (0–10 NRS), change from baseline (hybrid-treatment estimand) TRIUMPH-1-OA · 12 mg
week 80
−3.5−1.5−1.9 (−2.5 to −1.4) pointsverified
Verbatim quotes (10)
  • WOMAC pain (0–10 NRS), change from baseline (hybrid-treatment estimand)
    was -3.96 with 9-mg, -3.74 with 12-mg retatrutide, and -2.12 with placebo (estimated treatment difference [ETD] vs. placebo [95% CI]: 9-mg: -1.83 [-2.37,-1.30];
  • WOMAC physical function (0–10 NRS), change from baseline (hybrid-treatment estimand)
    Physical Function score (0.22) (0.22) Treatment comparison -1.83 (-2.40, - -1.77 (-2.34, - __
  • WOMAC pain (0–10 NRS), change from baseline (hybrid-treatment estimand)
    12-mg: -1.61 [-2.16,-1.07], all p<0.001; Table 2, Fig. 1)
  • WOMAC physical function (0–10 NRS), change from baseline (hybrid-treatment estimand)
    -3.64 (0.20) -3.57 (0.20) -1.80 -3.21 (0.18) -3.42 (0.21) -3.48 (0.19) -1.53
  • WOMAC pain (0–10 NRS), change from baseline (hybrid-treatment estimand)
    baseline to week 80 was -3.22 (4-mg) [key secondary endpoint], -3.48 (9-mg), and -3.64 (12- mg) and -1.87 (placebo) (ETD vs. placebo [95% CI]: 4-mg: -1.35 [-1.92,-0.78]; 9-mg: -1.61 [- 2.20,-1.02]; 12-mg: -1.77 [-2.34,-1.20]; all p<0.001; Table 2, Fig. 1)
  • WOMAC physical function (0–10 NRS), change from baseline (hybrid-treatment estimand)
    -3.64 (0.20) -3.57 (0.20) -1.80 -3.21 (0.18) -3.42 (0.21) -3.48 (0.19) -1.53
  • WOMAC pain (0–10 NRS), change from baseline (hybrid-treatment estimand)
    baseline to week 80 was -3.22 (4-mg) [key secondary endpoint], -3.48 (9-mg), and -3.64 (12- mg) and -1.87 (placebo) (ETD vs. placebo [95% CI]: 4-mg: -1.35 [-1.92,-0.78]; 9-mg: -1.61 [- 2.20,-1.02]; 12-mg: -1.77 [-2.34,-1.20]; all p<0.001; Table 2, Fig. 1)
  • WOMAC physical function (0–10 NRS), change from baseline (hybrid-treatment estimand)
    -3.64 (0.20) -3.57 (0.20) -1.80 -3.21 (0.18) -3.42 (0.21) -3.48 (0.19) -1.53
  • WOMAC pain (0–10 NRS), change from baseline (hybrid-treatment estimand)
    baseline to week 80 was -3.22 (4-mg) [key secondary endpoint], -3.48 (9-mg), and -3.64 (12- mg) and -1.87 (placebo) (ETD vs. placebo [95% CI]: 4-mg: -1.35 [-1.92,-0.78]; 9-mg: -1.61 [- 2.20,-1.02]; 12-mg: -1.77 [-2.34,-1.20]; all p<0.001; Table 2, Fig. 1)
  • WOMAC physical function (0–10 NRS), change from baseline (hybrid-treatment estimand)
    -3.64 (0.20) -3.57 (0.20) -1.80 -3.21 (0.18) -3.42 (0.21) -3.48 (0.19) -1.53

Ongoing outcome trials

TrialMoleculePopulationPrimary endpointnRegistry statusPrimary completionRegistry
TRIUMPH-OUTCOMESRetatrutideObesity + CVD
Obesity (BMI ≥27) + ASCVD, with or without T2D
MACE10000active not recruiting2029-02NCT06383390

Registered trials (15)

From ClinicalTrials.gov and the atlas registry sweep; phase 3 and outcome trials first.

TrialIndicationPhaseStatusStart → primary completionnResultRegistry
TRIUMPH-9
A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight
ObesityPhase 3active not recruiting2026-01 → 2028-10600active not recruitingNCT07357415
TRIUMPH-8
A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight
ObesityPhase 3active not recruiting2025-11 → 2027-06250active not recruitingNCT07232719
SYNERGY-Outcomes
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
MASHPhase 3recruiting2025-10 → 2030-084500recruitingNCT07165028
TRIUMPH-7
A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain
ObesityPhase 3active not recruiting2025-05 → 2027-09586active not recruitingNCT07035093
TRIUMPH-6
A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity
ObesityPhase 3active not recruiting2025-03 → 2028-04643active not recruitingNCT06859268
TRIUMPH-5
A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity
ObesityPhase 3active not recruiting2024-11 → 2026-11800active not recruitingNCT06662383
TRIUMPH-OUTCOMES
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
CV outcomesPhase 3active not recruiting2024-04 → 2029-0210000NCT06383390
TRANSCEND-T2D-1
Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)
T2DPhase 3completed2024-04 → 2026-01537Completed; arm-level results are in the atlas maps (Effect vs cost, Arms)NCT06354660
TRANSCEND-T2D-3
Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)
T2DPhase 3active not recruiting2024-03 → 2026-10320active not recruitingNCT06297603
TRANSCEND-T2D-2
Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)
T2DPhase 3active not recruiting2024-02 → 2026-081250Primary endpoint met (HbA1c non-inferiority of 12 mg vs semaglutide 2 mg): HbA1c −2.2 (9 and 12 mg) vs −1.8 %-points, weight −19.5 / −20.9 % vs −9.4 % at 80 weeks (efficacy estimand); topline press release, Oct 2026NCT06260722
TRIUMPH-4 / TRIUMPH-1-OA
A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee
CV outcomesPhase 3completed2023-08 → 2025-11445Completed; results not yet publicNCT05931367
TRIUMPH-1
A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight
ObesityPhase 3completed2023-07 → 2026-042335Completed; arm-level results are in the atlas maps (Effect vs cost, Arms)NCT05929066
TRIUMPH-2
A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight
ObesityPhase 3completed2023-07 → 2026-061152Completed; arm-level results are in the atlas maps (Effect vs cost, Arms)NCT05929079
NCT05936151
A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes
CKDPhase 2completed2023-07 → 2025-10146Completed; results not in the atlas yetNCT05936151
TRIUMPH-3
A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease
ObesityPhase 3completed2023-05 → 2026-041946Completed; results not in the atlas yetNCT05882045

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: Retatrutide. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/retatrutide/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.